Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -26.55 Million SEK | -23.58% |
| 2022 | -21.48 Million SEK | 1.07% |
| 2021 | -21.72 Million SEK | -19.64% |
| 2020 | -18.15 Million SEK | 2.58% |
| 2019 | -18.63 Million SEK | -26.77% |
| 2018 | -14.7 Million SEK | -96.79% |
| 2017 | -7.47 Million SEK | -50.91% |
| 2016 | -4.95 Million SEK | -30.83% |
| 2015 | -3.78 Million SEK | -129.73% |
| 2014 | -1.64 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -7.84 Million SEK | 3.09% |
| 2024 Q2 | -5.18 Million SEK | 33.95% |
| 2023 Q3 | -6.08 Million SEK | 13.38% |
| 2023 Q4 | -8.09 Million SEK | -32.94% |
| 2023 Q2 | -7.02 Million SEK | -31.22% |
| 2023 FY | -26.55 Million SEK | -23.58% |
| 2023 Q1 | -5.35 Million SEK | 24.47% |
| 2022 Q4 | -7.09 Million SEK | -171.02% |
| 2022 FY | -21.48 Million SEK | 1.07% |
| 2022 Q3 | -2.61 Million SEK | 62.32% |
| 2022 Q2 | -6.94 Million SEK | -43.57% |
| 2022 Q1 | -4.83 Million SEK | 15.65% |
| 2021 Q3 | -4.71 Million SEK | 20.34% |
| 2021 Q4 | -5.73 Million SEK | -21.69% |
| 2021 FY | -21.72 Million SEK | -19.64% |
| 2021 Q1 | -5.33 Million SEK | -8.92% |
| 2021 Q2 | -5.91 Million SEK | -10.85% |
| 2020 Q3 | -5.32 Million SEK | -44.26% |
| 2020 Q4 | -4.89 Million SEK | 8.04% |
| 2020 Q1 | -3.67 Million SEK | 35.08% |
| 2020 FY | -18.15 Million SEK | 2.58% |
| 2020 Q2 | -3.69 Million SEK | -0.49% |
| 2019 Q3 | -4.28 Million SEK | 6.11% |
| 2019 Q4 | -5.65 Million SEK | -32.0% |
| 2019 FY | -18.63 Million SEK | -26.77% |
| 2019 Q1 | -4.13 Million SEK | 12.81% |
| 2019 Q2 | -4.56 Million SEK | -10.48% |
| 2018 Q1 | -2.5 Million SEK | -17.28% |
| 2018 Q4 | -4.74 Million SEK | -34.74% |
| 2018 Q3 | -3.51 Million SEK | 10.64% |
| 2018 Q2 | -3.93 Million SEK | -57.17% |
| 2018 FY | -14.7 Million SEK | -96.79% |
| 2017 Q4 | -2.13 Million SEK | -1.71% |
| 2017 FY | -7.47 Million SEK | -50.91% |
| 2017 Q1 | -1.28 Million SEK | -33.23% |
| 2017 Q2 | -1.95 Million SEK | -52.07% |
| 2017 Q3 | -2.1 Million SEK | -7.64% |
| 2016 Q4 | -963 Thousand SEK | 0.0% |
| 2016 FY | -4.95 Million SEK | -30.83% |
| 2015 FY | -3.78 Million SEK | -129.73% |
| 2014 FY | -1.64 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 89.318% |
| Ziccum AB (publ) | -21.41 Million SEK | -24.015% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -48.371% |
| BioArctic AB (publ) | 229.24 Million SEK | 111.583% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -5962.557% |
| Mendus AB (publ) | -101.61 Million SEK | 73.869% |
| Genovis AB (publ.) | 61.5 Million SEK | 143.177% |
| Intervacc AB (publ) | -102.85 Million SEK | 74.182% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -60.709% |
| Active Biotech AB (publ) | -45.8 Million SEK | 42.022% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 318.21% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 53.267% |
| Aptahem AB (publ) | -11.11 Million SEK | -138.948% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 91.46% |
| Kancera AB (publ) | -64.88 Million SEK | 59.078% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 78.423% |
| Saniona AB (publ) | -95.81 Million SEK | 72.285% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -118.948% |
| Biovica International AB (publ) | -124.82 Million SEK | 78.727% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 37.11% |
| AcouSort AB (publ) | -17.08 Million SEK | -55.387% |
| Xintela AB (publ) | -54.08 Million SEK | 50.901% |
| Abliva AB (publ) | -95.5 Million SEK | 72.197% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 91.877% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 593.019% |
| OncoZenge AB (publ) | -15.9 Million SEK | -66.985% |
| Amniotics AB (publ) | -30.87 Million SEK | 13.981% |
| 2cureX AB (publ) | -32.51 Million SEK | 18.341% |
| CombiGene AB (publ) | -35.66 Million SEK | 25.547% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -107.0% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 94.304% |
| Camurus AB (publ) | 431.44 Million SEK | 106.155% |
| Corline Biomedical AB | -1.8 Million SEK | -1367.883% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 85.069% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 28.37% |
| I-Tech AB | 20.2 Million SEK | 231.436% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 96.807% |
| Cyxone AB (publ) | -22.98 Million SEK | -15.507% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 70.948% |
| Biosergen AB | -27.03 Million SEK | 1.786% |
| Cantargia AB (publ) | -280.02 Million SEK | 90.517% |
| NextCell Pharma AB | -41.95 Million SEK | 36.716% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 85.22% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -61.935% |
| Nanologica AB (publ) | -75.15 Million SEK | 64.669% |
| SynAct Pharma AB | -215.81 Million SEK | 87.696% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 39.724% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -11.868% |
| LIDDS AB (publ) | -40.2 Million SEK | 33.955% |
| Lipum AB (publ) | -37.17 Million SEK | 28.576% |
| BioInvent International AB (publ) | -330.3 Million SEK | 91.961% |
| Alzinova AB (publ) | -16.48 Million SEK | -61.129% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 89.34% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -167.412% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 76.568% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -25.902% |
| Simris Alg AB (publ) | -37.3 Million SEK | 28.819% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 82.513% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 93.159% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 75.703% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -127.385% |